Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JC, Zhou C, Vokes E. Manegold C, et al. Among authors: huber rm. J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub 2016 Oct 8. J Thorac Oncol. 2017. PMID: 27729297 Free article. Review.
[Therapy for non-small-cell lung carcinoma (NSCLC) in stage IV].
Deppermann KM, Huber RM, Laack E, Reck M, Serke M, von Pawel J. Deppermann KM, et al. Among authors: huber rm. Onkologie. 2006 Sep;29 Suppl 2:15-9. doi: 10.1159/000094950. Epub 2006 Sep 6. Onkologie. 2006. PMID: 16974123 Review. German. No abstract available.
[Current developments and perspectives in targeted therapies].
Dickgreber N, Huber RM, Reck M, Reinmuth N, Schütte W, Serke M, Wolf J. Dickgreber N, et al. Among authors: huber rm. Onkologie. 2010;33 Suppl 5:2-11. doi: 10.1159/000313971. Epub 2010 May 14. Onkologie. 2010. PMID: 20523101 Free article. Review. German.
Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial.
Fink TH, Huber RM, Heigener DF, Eschbach C, Waller C, Steinhauer EU, Virchow JC, Eberhardt F, Schweisfurth H, Schroeder M, Ittel T, Hummler S, Banik N, Bogenrieder T, Acker T, Wolf M; “Aktion Bronchialkarzinom” (ABC Study Group). Fink TH, et al. Among authors: huber rm. J Thorac Oncol. 2012 Sep;7(9):1432-9. doi: 10.1097/JTO.0b013e318260de75. J Thorac Oncol. 2012. PMID: 22895140 Free article. Clinical Trial.
Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells.
Kobold S, Völk S, Clauditz T, Küpper NJ, Minner S, Tufman A, Düwell P, Lindner M, Koch I, Heidegger S, Rothenfuer S, Schnurr M, Huber RM, Wilczak W, Endres S. Kobold S, et al. Among authors: huber rm. J Thorac Oncol. 2013 Aug;8(8):1032-42. doi: 10.1097/JTO.0b013e31829923c8. J Thorac Oncol. 2013. PMID: 23774470 Free article.
277 results